Big Picture Bio Founded to Identify, Design and Optimise Promising Cancer Combination Therapies

Big Picture Bio was founded to identify, design and optimise promising cancer combination therapies.

The company uses a generative world model to understand interactions between tumours, immune cells and surrounding tissue across disease sites and patient subgroups.

It combines AI-driven modelling with targeted wet-lab validation to find combinations more likely to work in patients.

The company closed a £1.5 million pre-seed round, co-led by Kadmos Capital and Exceptional Ventures, with participation from Gloucester Ventures and angel investor John White.

It also secured £700,000 in non-dilutive Innovate UK funding, bringing total early funding to £2.2 million.

Founded by Deep Science Ventures veterans Dr Kerstin Papenfuss (CEO) and Dr Mark Hammond (CTO), it brings experience from Deep Science Ventures, AstraZeneca, Exscientia and PhoreMost.

Big Picture Bio is initially focused on cancer and immune-mediated diseases, aiming to design optimal drug combinations and sequencing to minimise residual disease.